Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 2
1969 2
1970 5
1971 6
1972 13
1973 14
1974 6
1975 9
1976 12
1977 13
1978 8
1979 6
1980 6
1981 4
1982 4
1983 14
1984 11
1985 12
1986 16
1987 12
1988 13
1989 19
1990 14
1991 29
1992 14
1993 31
1994 22
1995 30
1996 38
1997 40
1998 43
1999 49
2000 77
2001 101
2002 130
2003 121
2004 167
2005 192
2006 239
2007 276
2008 286
2009 344
2010 415
2011 532
2012 580
2013 618
2014 752
2015 750
2016 800
2017 775
2018 830
2019 883
2020 1035
2021 1105
2022 657
Text availability
Article attribute
Article type
Publication date

Search Results

10,845 results
Results by year
Filters applied: . Clear all
Page 1
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. Wang E, et al. Among authors: cho h. N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110. N Engl J Med. 2022. PMID: 35196427 Free PMC article.
Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells.
North K, Benbarche S, Liu B, Pangallo J, Chen S, Stahl M, Bewersdorf JP, Stanley RF, Erickson C, Cho H, Pineda JMB, Thomas JD, Polaski JT, Belleville AE, Gabel AM, Udy DB, Humbert O, Kiem HP, Abdel-Wahab O, Bradley RK. North K, et al. Among authors: cho h. Nat Biotechnol. 2022 Jul;40(7):1103-1113. doi: 10.1038/s41587-022-01224-2. Epub 2022 Mar 3. Nat Biotechnol. 2022. PMID: 35241838
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY. Hong JY, et al. Among authors: cho hj. Genome Med. 2022 Jan 6;14(1):1. doi: 10.1186/s13073-021-00995-8. Genome Med. 2022. PMID: 34986867 Free PMC article. Clinical Trial.
10,845 results
You have reached the last available page of results. Please see the User Guide for more information.